Shielded HSCs from CD45-targeting immunotherapy (Cimeio Therapeutics)

N/A

Report date: 2025/09/01 16:35:29

Base Information

Drug NameShielded HSCs from CD45-targeting immunotherapy (Cimeio Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionT lymphocytes stimulantsImmunostimulantsAnti-CD45

TargetsLeukocyte common antigen

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCimeio Therapeutics AG

China Registration ClassN/A

Develop Information

Active CompaniesCimeio Therapeutics AG

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A